



Laboratorios Karizoo, S.A. De C.V. (Mexico)  
 Balance Sheet As At 31st March 2019  
 All amounts are in Mexican Peso unless otherwise stated

	Notes	As at 31st Mar 2019	As at 31st Mar 2018
<b>A ASSETS</b>			
<b>1. Non-current assets</b>			
(a) Property, plant and equipment	3	1,028,129	1,009,919
(b) Financial Assets			
(i) Loans	4	146,383	88,254
(c) Other non-current assets	5	525,849	423,676
<b>Total non-current assets</b>		<b>1,700,361</b>	<b>1,521,849</b>
<b>2. Current assets</b>			
(a) Inventories	6	14,350,119	10,570,591
(b) Financial Assets			
(i) Trade receivables	7	8,758,943	7,230,211
(ii) Cash and cash equivalents	8	1,916,032	1,580,584
(c) Other current assets	9	5,070,306	3,869,792
<b>Total current assets</b>		<b>30,095,400</b>	<b>23,251,177</b>
<b>Total assets</b>		<b>31,795,761</b>	<b>24,773,027</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Equity share capital	10	6,110,000	6,110,000
(b) Other Equity	11	3,388,264	2,570,620
<b>Total equity</b>		<b>9,498,264</b>	<b>8,680,620</b>
<b>2 Liabilities</b>			
<b>Current liabilities</b>			
(a) Financial Liabilities			
(i) Trade payables	12	21,897,979	14,097,432
(b) Other current liabilities	13	65,791	58,477
(c) Current tax liabilities (Net)	14	333,727	1,936,497
<b>Total current Liabilities</b>		<b>22,297,497</b>	<b>16,092,407</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>31,795,761</b>	<b>24,773,027</b>
Significant Accounting Policies & Notes on Accounts	2		
As per our report of event date	FOR AND ON BEHALF OF THE BOARD OF DIRECTORS		
HLB LEÓN TELLO GARCÍA Y ASOCIADOS, S.C. Auditors & Consultants	 LABORATORIOS KARIZOO S.A. DE C.V. AV. FUENTES No. 70, BODEGA 5 PARQUE INDUSTRIAL FINSA EL MARQUES, QUERETARO C.P. 76246 RFC: LKA0310028L0 TEL: 442 962 09 47 , 48, 49 Director		
 HLB Querétaro León Tello García y Asociados SC LTG080207TP5			
Place : Queretaro, Qro., Mexico Date : May 10, 2019.			




Laboratorios Karizoo, S.A. De C.V. (Mexico)  
 Profit And Loss for the Year Ended 31st March 2019  
 All amounts are in Mexican Peso

Particulars		Notes	Year ended 31 Mar 2019	Year ended 31 Mar 2018
I	Revenue From Operations	15	64,933,115	55,423,493
II	Other Income	16	269,897	1,637,908
III	<b>Total Income (I+ II)</b>		<b>65,203,012</b>	<b>57,061,401</b>
IV	<b>EXPENSES</b>			
(a)	Cost of materials consumed	17	49,179,867	34,470,527
(b)	Changes in inventories of finished goods and work-in-progress & intermediates	18	(4,957,791)	(409,526)
(c)	Employee benefits expense	19	7,157,181	6,333,516
(d)	Finance costs	20	238,078	97,364
(e)	Depreciation and amortization expense	21	384,987	139,196
(f)	Other expenses	22	11,296,082	12,828,209
	<b>Total expenses (IV)</b>		<b>63,298,403</b>	<b>53,459,285</b>
V	<b>Profit/(loss) before tax</b>		<b>1,904,609</b>	<b>3,602,116</b>
VI	<b>Tax expense</b>	23		
	Current tax		1,086,966	1,340,810
	<b>Total tax expenses</b>		<b>1,086,966</b>	<b>1,340,810</b>
VII	<b>Profit/(loss) after tax (V-VI)</b>		<b>817,643</b>	<b>2,261,306</b>
VIII	<b>Earnings per equity share:</b>			
	(1) Basic		134.04	370.71
	(2) Diluted		134.04	370.71

As per our report of event date

HLB LEÓN TELLO GARCÍA Y ASOCIADOS, S.C..  
 Auditors & Consultants




HLB Querétaro  
 León Tello García y Asociados SC  
 LTG080207TP5

Place : Queretaro, Qro., Mexico.  
 Date : May 10, 2019.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

LABORATORIOS KARIZOO S.A. DE C.V.  
 AV. FUENTES No. 70, BODEGA 8  
 PARQUE INDUSTRIAL FINSA  
 EL MARQUES, QUERETARO C.P. 76246  
 RFC: LKA0310028L0  
 TEL: 442 962 09 47, 48, 49

Director





**Laboratorios Karizoo sa de cv (Mexico)**  
**Notes forming part of the financial statements**

**Note**

**1 Legal status and principal activities**

Laboratorios Karizoo sa de cv ("The Company"), incorporated in Mexico, specialized in animal health, offers a vademécum of pharmacological injectables, oral solutions and proprietary medicated premixes that are distributed throughout the country.

Laboratorios Karizoo, sa de cv is 50% subsidiary company of Laboratorios Karizoo, sa., and 50% Subsidiary of Vila Vina Participacions S.L., both located in Barcelona (Spain), dedicated to the manufacture and distribution of animal health and nutrition products.

**2 Significant accounting policies**

**2.1 Basis of accounting and preparation of financial statements**

The Financial Statements have been prepared on accrual basis under the historical cost convention except for certain categories of fixed assets that are carried at revalued amounts.

The financial statements of Laboratorios Karizoo sa de cv ('the Company') have been prepared, in accordance with with the Accounting policies and standards in Mexico. The Financial Statements have been prepared on accrual basis.

Effective 1 June 2016, Alivira Animal Health Limited, Ireland (step down subsidiary of Sequent Scientific Limited) acquired stake of 60% in Vila Vina Participacions SL which is the holding company of Laboratorios Karizoo SA.

The financial statements are prepared for the period 1 April 2018 to 31 March 2019 for the purpose of consolidation with its ultimate holding Company 'Sequent Scientific Limited'

**2.2 Tangible fixed assets**

Fixed assets are carried at cost less accumulated depreciation and impairment losses, if any. The cost of fixed assets comprise its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than the subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets to the date the asset is ready for its intended use. Exchange differences arising on restatement/ settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

**2.3 Depreciation**

Depreciation is provided under the straight-line method based on the useful lives:

Nature of Asset	Useful life in periods (range)
Buildings	10 - 75
Plant and Machinery	2 -25
Technical Facilities	10 - 30
Technical Installations	2 - 15
Office Equipment	3 - 10
Vehicles	2 - 8
Furniture and Fixtures	5 - 15



## 2.4 Impairment of assets

The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment if any indication of impairment exists. The following intangible assets are tested for impairment each financial period even if there is no indication that the asset is impaired:

(a) an intangible asset that is not yet available for use; and (b) an intangible asset that is amortised over a period exceeding ten periods from the date when the asset is available for use.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognised for such excess amount. The impairment loss is recognised as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognised for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets

## 2.5 Inventory

Inventories comprises of raw materials and finished goods. These are valued at the lower of cost and net realizable value. Cost is determined on First in First out basis for finished goods - 'At material cost, conversion costs and an appropriate share of production overheads.

## 2.6 Revenue recognition

Revenue from export sales is recognized on the basis of the shipping bills for exports. Revenue from domestic sales is recognized based on the passage of title to goods which generally coincides with dispatch. Sales include excise duty and are stated net of discounts, other taxes, and sales returns.

Dividend income is recognised when the right to receive the same is established.

Interest income is recognised on an accrual basis.

## 2.7 Taxes on income

Income Tax comprises the current tax provision. Current tax is the amount of tax payable on the taxable income for the period.

## 2.8 Earnings per share (EPS)


In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.

## 2.9 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

## 2.10 Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that there is no uncertainty in receiving the claims.





### 2.11 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.


### 2.12

#### Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

### 2.13 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

A handwritten signature in blue ink, consisting of a stylized initial 'S' followed by a horizontal line and a large, circular flourish.




**LABORATORIOS KARIZOO, S.A. DE C.V. (Mexico)**  
**Notes to the financial statements for the Year ended 31st March 2019**  
**All amounts are in Mexican Peso unless otherwise stated**

Particulars	As at 31st Mar 2019	As at 31st Mar 2018
<b>3 Property, plant and equipment</b>		
Furniture and fixtures	131,963	39,262
Computers	112,131	154,442
Plant and machinery	88,409	92,044
Vehicles	695,627	724,171
<b>Total</b>	<b>1,028,129</b>	<b>1,009,919</b>
<b>4 Financial assets - Long term loans and advances</b>		
Security Deposits	146,383	88,254
<b>Total</b>	<b>146,383</b>	<b>88,254</b>
<b>5 Other non-current assets</b>		
Prepaid expenses	525,849	423,676
<b>Total</b>	<b>525,849</b>	<b>423,676</b>
<b>6 Inventories</b> <b>(At lower of cost and net realisable value)</b>		
Raw materials and packing materials	1,015,377	2,193,640
	<b>1,015,377</b>	<b>2,193,640</b>
Work-in-progress and intermediates	681,421	1,945,757
Finished goods	8,889,377	5,219,137
Goods-in transit - FG	3,763,944	1,212,057
	<b>12,653,321</b>	<b>6,431,194</b>
<b>Total</b>	<b>14,350,119</b>	<b>10,570,591</b>
<b>7 Trade receivables</b>		
(a) Unsecured, considered good	8,675,919	7,180,543
	<b>8,675,919</b>	<b>7,180,543</b>
Other Debts		
(a) Unsecured, considered good	83,024	49,668
	<b>83,024</b>	<b>49,668</b>
<b>Total</b>	<b>8,758,943</b>	<b>7,230,211</b>
<b>8 Cash and cash equivalents</b>		
Cash with Employees	48,271	42,271
- In current accounts	1,867,761	1,538,313
<b>Total</b>	<b>1,916,032</b>	<b>1,580,584</b>
<b>9 Other current assets</b>		
Advance to supplier	52,510	-
Balances with government authorities	4,252,435	3,149,417
Advance Income-Tax including tax deducted at source	765,360	720,375
	<b>5,070,306</b>	<b>3,869,792</b>



LABORATORIOS KARIZOO, S.A. DE C.V. (Mexico)  
Notes to the financial statements for the Year ended 31st March 2019  
All amounts are in Mexican Peso unless otherwise stated

Particulars		As at 31st Mar 2019	As at 31st Mar 2018
12	<b>Trade payable</b>		
	Trade payable	21,897,979	14,097,432
	<b>Total</b>	<b>21,897,979</b>	<b>14,097,432</b>
13	<b>Other Current Liabilities</b>		
	Statutory remittances	65,791	58,477
	<b>Total</b>	<b>65,791</b>	<b>58,477</b>
14	<b>Current tax liabilities (Net)</b>		
	Value added Tax Payable/(Recoverable)	225,745	445,244
	Withholding TAXES Payable /(Recoverable)	107,982	1,491,253
	<b>Total</b>	<b>333,727</b>	<b>1,936,497</b>





LABORATORIOS KARIZOO, S.A. DE C.V. (Mexico)

Notes to accounts

All amounts are in Mexican Peso unless otherwise stated

	As at 31st Mar 2019	As at 31st Mar 2018
<b>10 Share capital</b>		
<b>(a) Authorised Share Capital</b>		
6110 share of Peso 1000 each	6,110,000	6,110,000
<b>(a) Issued Share Capital</b>		
6110 share of Peso 1000 each	6,110,000	6,110,000
	<u>6,110,000</u>	<u>6,110,000</u>

Notes :

(i) Reconciliation of the number of shares and amount outstanding at the beginning and end of the reporting period

	As at 31st Mar 2019		As at 31st Mar 2018	
	No. of Shares	Amount	No. of Shares	Amount
No. Equity shares	6,110	6,110,000	6,110	6,110,000
Add : Shares issued during the period	-	-	-	-
Shares outstanding at the end of the period	<u>6,110</u>	<u>6,110,000</u>	<u>6,110</u>	<u>6,110,000</u>

(ii) Terms / Rights attached to Equity Shares

In the Event of liquidation of the company, the shareholders of the equity shares will be entitled to receive the remaining assets of the company, after distribution of the all preferential amounts, if any. The distribution will be in the proportion to the number of equity shares held by the share holders

(iii) Details of Shares held by each share holder holding more than 5% shares

<u>Name of Share Holders</u>	<u>No. of Shares</u>	<u>% holding</u>	<u>No. of Shares</u>	<u>% holding</u>
Vila Viña Participacions S.L.	3,055	50%	3,055	50%
Laboratorios Karizoo, S.A.	3,055	50%	3,055	50%

	As at 31st Mar 2019	As at 31st Mar 2018
<b>11 a) Retained Earnings</b>		
<b>Opening Balance</b>	5,491,285	3,229,980
Add: Profit / (Loss) for the year	817,644	2,261,305
	<u>6,308,929</u>	<u>5,491,285</u>
<b>ii) Other Reserves</b>		
General reserve	(2,920,667)	(2,920,668)
	<u>(2,920,667)</u>	<u>(2,920,668)</u>
<b>Other Equity (Total)</b>	<u>3,388,261</u>	<u>2,570,617</u>



	Year ended 31 Mar 2019	Year ended 31 Mar 2018
<b>15 Revenue from operations</b>		
a) Sale of products	63,958,761	54,960,042
d) Other operating revenues	974,354	463,450
<b>Total</b>	<b>64,933,115</b>	<b>55,423,493</b>
<b>16 Other Income</b>		
Interest income	34	49
Other non-operating income	269,862	9,538
Net gain on foreign currency transactions and translation	-	1,628,321
<b>Total</b>	<b>269,897</b>	<b>1,637,908</b>
<b>17 Cost of materials consumed</b>		
Opening stock	2,193,640	713,595
Add: Purchases	48,001,603	35,950,572
Less: Closing stock	1,015,377	2,193,640
<b>Cost of materials consumed</b>	<b>49,179,867</b>	<b>34,470,527</b>
<b>18 Changes in inventories of finished goods and work-in-progress &amp; intermediates</b>		
<b>Opening stock</b>		
Work-in-progress and intermediates	1,945,757	2,082,639
Finished goods	6,431,194	5,884,786
	<b>8,376,951</b>	<b>7,967,424</b>
<b>Closing stock</b>		
Work-in-progress and intermediates	681,421	1,945,757
Finished goods	12,653,321	6,431,194
	<b>13,334,742</b>	<b>8,376,951</b>
<b>Net (increase) / decrease</b>	<b>(4,957,791)</b>	<b>(409,526)</b>
<b>19 Employee benefits expense</b>		
Salaries and wages	6,905,930	6,232,641
Staff welfare expenses	251,251	100,875
<b>Total</b>	<b>7,157,181</b>	<b>6,333,516</b>
<b>20 Finance costs</b>		
Interest expense	202,132	73,148
Other borrowing costs	35,946	24,215
<b>Total</b>	<b>238,078</b>	<b>97,364</b>
<b>21 Depreciation and amortization expense</b>		
Tangible assets	384,987	139,196
<b>Total</b>	<b>384,987</b>	<b>139,196</b>
<b>22 Other expenses</b>		
Travel expenses	1,669,481	1,124,197
Communication expenses	175,067	176,004
Consumables	241,825	251,648
Legal and Professional charges	1,429,823	1,221,470
Freight and forwarding	667,583	804,451
Power and fuel	777,800	749,086
Rent	1,371,736	1,234,937
Analytical charges	552,463	633,751
Repairs to buildings	26,801	-
Repairs to others	291,442	218,324
Insurance	220,300	281,710
Advertisement and selling expenses	2,038,058	2,629,785
Marketing Expenses	500,183	431,285
Rates and taxes	474,993	489,501
Net loss on foreign currency transactions and translation	782,978	2,035,591
Other expenses	75,549	546,470
<b>Total</b>	<b>11,296,082</b>	<b>12,828,209</b>
<b>23 Tax expense</b>		
Current tax	1,086,966	1,340,810
<b>Total</b>	<b>1,086,966</b>	<b>1,340,810</b>
<b>24 Earning per Share</b>		
Issued No of Equity shares	6,100	6,100
Profit / (Loss) for the year	817,643	2,261,306
Basic Earning Per share	134.04	370.71
Diluted Earning Per share	134.04	370.71
<b>25 Segment Information</b>		
Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the internal reporting system.		
<b>Primary Segment : Business Segment</b>		
The Company through its subsidiaries is primarily engaged in the business of trading and marketing of Pharmaceutical products. Considering the nature of the business and the financial reporting of the company, the company has only one business segment as the primary reportable segment.		
All the activities of the company are in Mexico.		